Real-world prospective study of recombinant human thrombopoietin for perioperative thrombocytopenia in chronic liver disease

Phase 4, open-label trial of recombinant human thrombopoietin in Thrombocytopenia and chronic liver disease (CLD) (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Proportion of patients with platelet count at least 75 x 10^9/L at postoperative day 7 without emergency treatment for bleeding. Planned start May 2026; status: not yet recruiting.